Teriparatide
A synthetic parathyroid hormone fragment and the first FDA-approved anabolic agent that builds new bone rather than merely slowing its loss.
Teriparatide (PTH(1-34); Forteo) is a synthetic 34-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous parathyroid hormone. It was the first FDA-approved anabolic bone agent for osteoporosis, stimulating new bone formation rather than only inhibiting resorption. Given as intermittent pulsatile subcutaneous injections, it activates the PTH/PTHrP receptor on osteoblasts to increase bone mineral density, improve trabecular microarchitecture, and reduce fracture risk. It is prescription-only and limited to a maximum of two years of treatment due to preclinical osteosarcoma findings.
Class
Synthetic 34-amino-acid parathyroid hormone fragment (PTH 1-34)
Half-life
~1 hour
Routes
Subcutaneous
Category
Hormone & Reproductive
Researched benefits
What it's studied for
Stimulates new bone formation
Unlike antiresorptive drugs, intermittent teriparatide preferentially activates osteoblasts over osteoclasts, driving net new bone formation. This anabolic action is its defining and FDA-recognized mechanism for osteoporosis.
Increases bone mineral density
By stimulating osteoblast activity and bone remodeling, teriparatide raises bone mineral density and improves trabecular microarchitecture, supported by multiple randomized controlled trials.
Reduces fracture risk
An American College of Physicians network meta-analysis found teriparatide reduces both clinical and radiographic vertebral fractures in postmenopausal women with osteoporosis, and it may be more effective than bisphosphonates in very high-risk patients.
Supports vertebral compression fracture healing
In osteoporotic vertebral compression fractures, teriparatide (especially combined with denosumab) produced higher rates of bone bridge formation, greater BMD gains, and faster pain relief than anti-resorptive agents alone.
May enhance implant osseointegration
Preclinical osteoporotic animal models show PTH supplementation consistently improves dental implant integration and peri-implant bone quality, though standardized human trials are still needed.
Mechanism
How it works
Teriparatide is the biologically active N-terminal 1-34 fragment of endogenous parathyroid hormone. It binds and activates the PTH/PTHrP receptor (PTH1R) on osteoblasts, the bone-forming cells.
The key to its anabolic effect is intermittent, pulsatile dosing. When PTH1R is stimulated in brief daily pulses rather than continuously, the receptor signaling preferentially favors osteoblast activity over osteoclast-driven resorption, resulting in net new bone formation. This is the opposite of the bone loss seen with chronically elevated parathyroid hormone.
Downstream, teriparatide increases bone remodeling with a positive balance toward formation, raises bone mineral density, and improves trabecular microarchitecture. It also stimulates local IGF-1 production in bone, which contributes to osteoblast proliferation and survival. This mechanism is distinct from antiresorptive agents such as bisphosphonates, which reduce bone breakdown but do not build new bone.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Clinical (FDA-approved)
- Dose
- Standard once-daily subcutaneous injection per Forteo labeling
- Frequency
- Once daily
- Timing
- Same time each day
- Duration
- Maximum 2 years (lifetime)
- Route
- Subcutaneous
Prescription-only; the intermittent daily pulse is essential to the anabolic effect. The source does not state a specific microgram amount.
- Teriparatide is a prescription medication administered by subcutaneous injection; dosing, prescription, reconstitution, and handling should be managed with a qualified provider.
- Treatment is limited to a maximum of two years over a patient's lifetime due to preclinical osteosarcoma findings.
- Indicated populations are postmenopausal women, men with osteoporosis, and patients with glucocorticoid-induced osteoporosis at high fracture risk.
Evidence
Research & clinical studies (6)
The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects: A systematic review
PTH (teriparatide) supplementation consistently improved dental implant integration and peri-implant bone quality in preclinical osteoporotic animal models, with combination approaches outperforming hormone therapy alone.
PMID 42218012Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians
This ACP network meta-analysis found teriparatide reduced both clinical and radiographic vertebral fractures in postmenopausal women and may be more effective than bisphosphonates in very high-risk patients.
PMID 36592455Medical practitioners' awareness and practices regarding bisphosphonate therapy and oral health risks: a Malaysian cross-sectional study
Malaysian practitioners had high awareness of bisphosphonate-related oral complications but significant gaps in guideline knowledge and preventive dental referral practices.
PMID 42216162Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adults with osteoporosis: A proportional hazards analysis
Among osteoporotic adults undergoing lumbosacral fusion, teriparatide showed no significant association with sacral fracture risk over two years, while a history of falls was the strongest predictor.
PMID 42205741Bone Bridge Effect for the Treatment of Acute Osteoporotic Vertebral Compression Fractures: A Multistrategic Approach Using an Anabolic Agent
Patients treated with anabolic agents—particularly teriparatide combined with denosumab—showed significantly higher bone bridge formation (51.8%), greater BMD gains, and faster pain relief than anti-resorptive agents alone.
PMID 42198860Consensus on the Treatment of Midshaft Clavicular Fractures in Collegiate Football Players: A Delphi Approach of Sports Medicine Teams
In treating midshaft clavicular fractures in collegiate athletes, bone stimulators and padding were used more commonly than teriparatide as adjuncts, with significant variation across the multidisciplinary panel.
PMID 42212197Combinations
Stacking & blends
Anabolic + Antiresorptive Combination
Accelerate healing of osteoporotic vertebral compression fractures
Cohort research found teriparatide combined with denosumab produced significantly higher rates of bone bridge formation, greater BMD increases, and faster pain relief than anti-resorptive agents alone.
Safety
Side effects & considerations
Contraindications & cautions
- Osteosarcoma risk (2-year treatment limit)
- Paget's disease of bone
- Prior radiation therapy to the skeleton
- Hypercalcemia
Teriparatide carries a moderate risk profile. Treatment is capped at a maximum of two years due to preclinical osteosarcoma findings. It is contraindicated in patients with conditions that increase baseline osteosarcoma risk, such as Paget's disease, prior skeletal radiation, and in those with pre-existing hypercalcemia. Review all contraindications with a qualified provider before use.
FAQ
Teriparatide — common questions
What is Teriparatide?
Teriparatide (PTH(1-34); Forteo) is a synthetic 34-amino-acid peptide corresponding to the biologically active N-terminal fragment of endogenous parathyroid hormone. It was the first FDA-approved anabolic bone agent for osteoporosis, stimulating new bone formation rather than merely inhibiting bone resorption.
How does Teriparatide differ from bisphosphonates?
Bisphosphonates are antiresorptive—they slow the breakdown of existing bone. Teriparatide is anabolic: given as intermittent pulsatile subcutaneous injections, it activates the PTH1R receptor on osteoblasts to build new bone, increasing bone mineral density and improving trabecular microarchitecture.
What is Teriparatide primarily studied for?
Bone formation, bone density increase, osteoporosis reversal, and fracture risk reduction. It is indicated for postmenopausal women, men with osteoporosis, and glucocorticoid-induced osteoporosis in patients at high fracture risk.
Why is Teriparatide limited to two years of use?
Treatment is capped at a maximum of two years over a lifetime because of preclinical osteosarcoma findings observed in animal studies. This limit is part of its FDA labeling.
What are the contraindications for Teriparatide?
Reported contraindications and considerations include conditions that raise baseline osteosarcoma risk—Paget's disease, prior radiation to the skeleton—as well as hypercalcemia and the two-year treatment limit itself.
How is Teriparatide administered?
It is given by subcutaneous injection once daily. The daily pulsatile dosing is essential to its anabolic, bone-building effect. It is prescription-only, so dosing and handling should be managed with a qualified provider.
Is Teriparatide FDA approved?
Yes. Forteo (NDA 021318) was FDA-approved on November 26, 2002, and the biosimilar Bonsity (NDA 210842) was approved in January 2020. Biosimilar teriparatide preparations are also available in multiple international markets.
